Swedish MTP Council updated the recommendations on FreeStyle Libre

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2.

In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs. The following recommendations are now made to regions:

• FreeStyle Libre and FreeStyle Libre 2 can be used in T2D patients treated with basal insulin in combination with mealtime insulin and having an Hba1c above 60 mmol/mol or recurrent severe hypoglycemic episodes despite efforts to adjust insulin doses. Attempts at lifestyle changes and optimization of treatment with non-insulin antidiabetic drugs should have been performed. Use for a limited time to optimize the treatment may also be possible;
• Otherwise, refrain from using FreeStyle Libre and FreeStyle Libre 2 in T2D;
• The MTP Council has not made any assessment regarding the handling of any personal data or for the cloud-based service Libre View that can be connected to the device. Each region must decide for itself.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).